Blood Cancer News and Research

RSS

Maraviroc reduces incidence of GvHD in blood cancer patients after bone marrow transplantation

An HIV drug that redirects immune cell traffic significantly reduces the incidence of a dangerous complication that often follows bone marrow transplants for blood cancer patients, according to research from the Perelman School of Medicine at the University of Pennsylvania that will be published today in the New England Journal of Medicine.

12 Jul 2012

CARHY announces comprehensive hematopoietic stem cell transplant service

Adding an impetus to the already existing image of Bangalore being a healthcare destination of India, Columbia Asia Referral Hospital, Yeshwanthpur (CARHY), announced comprehensive bone marrow transplant (stem cell transplant) service on Thursday.

23 Jun 2012

Researchers engineer nanoparticles that show great promise for MM

Researchers from the University of Notre Dame have engineered nanoparticles that show great promise for the treatment of multiple myeloma (MM), an incurable cancer of the plasma cells in bone marrow.

16 Jun 2012

US Oncology Research, MMRF partner to participate in CoMMpass study

The Multiple Myeloma Research Foundation (MMRF) today announced an alliance with US Oncology Research to participate in the landmark CoMMpass (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) study sponsored by the MMRF.

14 Jun 2012

Diabetes linked to increased blood cancer risk

Patients with Type 2 diabetes are at an increased risk for developing lymphoma, suggest findings from a US study.

11 Jun 2012

Patients with type 2 diabetes have 20% increased risk of blood cancers

Patients with type 2 diabetes have a 20 percent increased risk of developing blood cancers, such as non-Hodgkin lymphoma, leukemia and myeloma, according to a new meta-analysis led by researchers at The Miriam Hospital.

6 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for the Company's oral anticancer compound, perifosine, in multiple myeloma, have been published in the online May 2012 issue of the British Journal of Haematology.

6 Jun 2012

Three-drug regimen provides rapid, durable responses for multiple myeloma

A three-drug treatment for the blood cancer multiple myeloma provided rapid, deep and potentially durable responses, researchers report today online in Blood, the Journal of the American Society of Hematology, and yesterday, Sunday, June 3, 2012, at the American Society of Clinical Oncology's Annual Meeting in Chicago, IL, USA.

5 Jun 2012

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma.

2 Jun 2012

LILRB2 receptor plays an important role in keeping stem cells from differentiating

An immune-system receptor plays an unexpected but crucially important role in keeping stem cells from differentiating and in helping blood cancer cells grow, researchers at UT Southwestern Medical Center report today in the journal Nature.

1 Jun 2012

Beyond chemotherapy to cure leukemia

The fight against cancer is not won in a single battle: long after a cancer has been beaten into remission, it can return. The reason for this is under debate, and much is unclear.

30 May 2012

JTCC to present latest findings in blood-cancer research at ASCO annual meeting

Physicians and researchers at John Theurer Cancer Center at HackensackUMC, one of the nation's top 50 cancer centers, will present the latest findings in blood-cancer research at the 2012 American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1-5. Their involvement in these studies is part of John Theurer Cancer Center's continued focus to bolster its research program.

30 May 2012

Scientists show why leukemia often returns

The fight against cancer is not won in a single battle: Long after a cancer has been beaten into remission, it can return. The reason for this is under debate, and much is unclear. New research led by Weizmann Institute scientists shows that, at least for one type of blood cancer, the source of cancer recurrence is in a set of cells that do not proliferate as quickly as regular cancer cells, and thus able to survive chemotherapy.

30 May 2012

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.

19 May 2012

Lenalidomide following stem cell transplant can halt progression of blood cancer

Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid-, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute.

17 May 2012

High-throughput sequencing can detect early signs of leukemia relapse

A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease.

17 May 2012

GSK, Epizyme and Constellation to develop next generation of epigenetic drugs for cancer

Scientific insights that expand on the teachings of Mendel, Watson and Crick, and underpinnings of the Human Genome Project are moving drug companies along the path to development of new medicines based on deeper insights into how factors other than the genetic code influence health and disease. That's the topic of the cover story in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), the world's largest scientific society.

19 Apr 2012

Soon a vaccine that targets 90% of all cancers

Results from the safety trial - on patients with blood cancer - found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition.

10 Apr 2012

High cancer treatment costs in the US – are they worth it? Study explores

Healthcare in the United States is costlier than care in other countries. A new analysis suggests that the cost may be worth it at least when it comes to cancer care. Americans may pay more for cancer treatment, but they also live longer after diagnosis — getting a benefit that offsets their higher health expenses the study says.

10 Apr 2012

MMRF announces unique oncology research partnership

The Multiple Myeloma Research Foundation (MMRF) today announced a unique oncology research partnership. This multi-year agreement involves several partners including the Translational Genomics Research Institute (TGen), Spectrum Health, and the Van Andel Research Institute.

3 Apr 2012